TY - JOUR
T1 - Multimodal MRI evaluation of parkinsonian limbic pathologies
AU - Wang, Ernest W.
AU - Du, Guangwei
AU - Lewis, Mechelle M.
AU - Lee, Eun Young
AU - De Jesus, Sol
AU - Kanekar, Sangam
AU - Kong, Lan
AU - Huang, Xuemei
N1 - Funding Information:
EWW received funding from the National Center for Advancing Translational Sciences. GD received funding from the National Institute of Environmental Health Sciences (NIEHS), the Michael J. Fox Foundation for Parkinson's Research, the Alzheimer's Association, Alzheimer's Research UK, the Weston Brain Institute, and the Department of Defense. MML received funding from the NIEHS, the Michael J. Fox Foundation for Parkinson's Research, the Alzheimer's Association, Alzheimer's Research UK, the Weston Brain Institute, Bristol Myers Squibb, Biogen, Pfizer, and the Department of Defense. EYL received funding from the NIEHS, Pfizer, and the Department of Defense. SDJ received funding from Bristol Myers Squibb and Pfizer. SK received no funding to disclose. LK received funding from the NIEHS, the Michael J. Fox Foundation for Parkinson's Research, the Alzheimer's Association, Alzheimer's Research UK, and the Weston Brain Institute. XH received funding from the NIEHS, the Michael J. Fox Foundation for Parkinson's Research, the Alzheimer's Association, Alzheimer's Research UK, the Weston Brain Institute, Bristol Myers Squibb, Biogen, Pfizer, and the Department of Defense. She has received consultant fees and honorarium from NIH.
Funding Information:
This study was funded by the following sources: National Institute of Neurological Disorders and Stroke , United States ( NS060722 and NS082151 to XH); the Hershey Medical Center Clinical Research Center , United States ( National Center for Research Resources , Grant UL1 RR033184 , i.e., now at the National Center for Advancing Translational Sciences , Grant UL1 TR000127 ); National Center for Advancing Translational Sciences , United States (TL1 TR002016 ); the PA Department of Health Tobacco CURE Funds , United States; the Translational Brain Research Center , United States; the Michael J. Fox Foundation for Parkinson's Research , United States; Alzheimer's Association , United States; Alzheimer's Research UK , United Kingdom; and the Weston Brain Institute , Canada.
Funding Information:
This study was funded by the following sources: National Institute of Neurological Disorders and Stroke, United States (NS060722 and NS082151 to XH); the Hershey Medical Center Clinical Research Center, United States (National Center for Research Resources, Grant UL1 RR033184, i.e., now at the National Center for Advancing Translational Sciences, Grant UL1 TR000127); National Center for Advancing Translational Sciences, United States (TL1 TR002016); the PA Department of Health Tobacco CURE Funds, United States; the Translational Brain Research Center, United States; the Michael J. Fox Foundation for Parkinson's Research, United States; Alzheimer's Association, United States; Alzheimer's Research UK, United Kingdom; and the Weston Brain Institute, Canada.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/4
Y1 - 2019/4
N2 - Previous multimodal magnetic resonance imaging (MRI) studies of parkinsonian syndromes have focused primarily on motor-related basal ganglia structures. The present study investigated MRI changes in nonmotor-related limbic structures in 35 Parkinson's disease, 16 multiple system atrophy parkinsonian subtype, 17 progressive supranuclear palsy, and 37 control subjects. Mean diffusivity (MD), fractional anisotropy, transverse relaxation rate (R2*), quantitative susceptibility mapping, and volume measurements were obtained from the amygdala, hippocampus, and nucleus accumbens (NAc) to examine differences between groups and to test for associations with clinical scores. Compared with controls, Parkinson's disease subjects had lower NAc volume; multiple system atrophy parkinsonian subtype subjects had higher NAc transverse relaxation rate; and progressive supranuclear palsy subjects had higher amygdala and hippocampus MD and lower hippocampus fractional anisotropy (p's ≤ 0.008). Among parkinsonian subjects, amygdala and hippocampus MD associated positively with Unified Parkinson's Disease Rating Scale nonmotor and activities of daily living scores (p's ≤ 0.005). Together, these findings support the inclusion of limbic structures in future MRI studies of parkinsonian syndromes.
AB - Previous multimodal magnetic resonance imaging (MRI) studies of parkinsonian syndromes have focused primarily on motor-related basal ganglia structures. The present study investigated MRI changes in nonmotor-related limbic structures in 35 Parkinson's disease, 16 multiple system atrophy parkinsonian subtype, 17 progressive supranuclear palsy, and 37 control subjects. Mean diffusivity (MD), fractional anisotropy, transverse relaxation rate (R2*), quantitative susceptibility mapping, and volume measurements were obtained from the amygdala, hippocampus, and nucleus accumbens (NAc) to examine differences between groups and to test for associations with clinical scores. Compared with controls, Parkinson's disease subjects had lower NAc volume; multiple system atrophy parkinsonian subtype subjects had higher NAc transverse relaxation rate; and progressive supranuclear palsy subjects had higher amygdala and hippocampus MD and lower hippocampus fractional anisotropy (p's ≤ 0.008). Among parkinsonian subjects, amygdala and hippocampus MD associated positively with Unified Parkinson's Disease Rating Scale nonmotor and activities of daily living scores (p's ≤ 0.005). Together, these findings support the inclusion of limbic structures in future MRI studies of parkinsonian syndromes.
UR - http://www.scopus.com/inward/record.url?scp=85061104845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061104845&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2019.01.004
DO - 10.1016/j.neurobiolaging.2019.01.004
M3 - Article
C2 - 30739076
AN - SCOPUS:85061104845
VL - 76
SP - 194
EP - 200
JO - Neurobiology of Aging
JF - Neurobiology of Aging
SN - 0197-4580
ER -